Search
Gemfibrozil
go.drugbank.com/drugs/DB01241ApprovedInvestigationalGemfibrozil is a fibric acid agent, similar to clofibrate, used to treat Type IIb, IV, and V hyperlipidemias. Gemfibrozil is not a first line treatment and is prescribed to patients who have not responded adequately to weight loss, diet,...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 InhibitorsBepridil
go.drugbank.com/drugs/DB01244ApprovedWithdrawnA long-acting, non selective, calcium channel blocker with significant anti-anginal activity. The drug produces significant coronary vasodilation and modest peripheral effects. It has antihypertensive and selective anti-arrhythmia activi...
Categories: P-glycoprotein inhibitors, Cytochrome P-450 SubstratesLapatinib
go.drugbank.com/drugs/DB01259ApprovedInvestigationalLapatinib is an anti-cancer drug developed by GlaxoSmithKline (GSK) as a treatment for solid tumours such as breast and lung cancer. It was approved by the FDA on March 13, 2007, for use in patients with advanced metastatic breast cancer...
Categories: P-glycoprotein inhibitors, Cytochrome P-450 SubstratesPaliperidone
go.drugbank.com/drugs/DB01267ApprovedInvestigationalPaliperidone is the primary active metabolite of risperidone. The mechanism of action is unknown but it is likely to act via a similar pathway to risperidone. It has been proposed that the drug's therapeutic activity in schizophrenia is ...
Categories: P-glycoprotein inhibitors, P-glycoprotein substratesSunitinib
go.drugbank.com/drugs/DB01268ApprovedInvestigationalSunitinib is a small-molecule multi-targeted receptor tyrosine kinase (RTK) inhibitor. On January 26, 2006, the agent was formally approved by the US FDA for the indications of treating renal cell carcinoma (RCC) and imatinib-resistant g...
Categories: P-glycoprotein inhibitors, P-glycoprotein substratesArformoterol
go.drugbank.com/drugs/DB01274ApprovedArformoterol is a bronchodilator. It works by relaxing muscles in the airways to improve breathing. Arformoterol inhalation is used to prevent bronchoconstriction in people with chronic obstructive pulmonary disease, including chronic br...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2A6 SubstratesHydralazine
go.drugbank.com/drugs/DB01275ApprovedInvestigationalOriginally developed in the 1950s as a malaria treatment, hydralazine showed antihypertensive ability and was soon repurposed. Hydralazine is a hydrazine derivative vasodilator used alone or as adjunct therapy in the treatment of hyperte...
Categories: Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A4 InhibitorsGlisoxepide
go.drugbank.com/drugs/DB01289InvestigationalGlisoxepide is one of the sulphonamide-derived oral antidiabetic drugs. It inhibits the uptake of bile acids into isolated rat hepatocytes. However it inhibits taurocholate uptake only in the absence of sodium ions. Glisoxepide uptake co...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C9 SubstratesBevantolol
go.drugbank.com/drugs/DB01295InvestigationalBevantolol is a beta-1 adrenoceptor antagonist that has been shown to be as effective as other beta blockers for the treatment of angina pectoris and hypertension. Mechanism of Action Animal experiments confirm both agonist and antagonis...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2D6 SubstratesPractolol
go.drugbank.com/drugs/DB01297ApprovedA beta-adrenergic antagonist that has been used in the emergency treatment of cardiac arrhythmias.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2D6 Substrates